Neurovascular Control and Blood Pressure Regulation in Humans

人类神经血管控制和血压调节

基本信息

  • 批准号:
    7650301
  • 负责人:
  • 金额:
    $ 37.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-01 至 2012-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal explores the balance between sympathetic vasoconstrictor activity and blood pressure regulation in younger and older humans. While baseline sympathetic nerve activity (MSNA) is stable in young normotensive males, there is wide inter-individual variation in baseline MSNA and no clear relationship between MSNA and arterial pressure. Additionally, sympathetic activity increases with normal aging but is not consistently associated with marked increases in arterial pressure. In this context, our recent studies suggest a balance among sympathetic activity, cardiac output, and vasoconstrictor responsiveness to adrenergic stimuli might explain how arterial pressure remains normal when baseline sympathetic activity is high. By exploring the following specific aims we test the overall hypotheses that high baseline sympathetic activity in normotensive younger and older subjects is balanced by reciprocal changes in cardiac output and vascular adrenergic responsiveness that limit the blood pressure raising impact of the sympathoexcitation. Specific Aim 1: We will test whether the reciprocal relationship between cardiac output (CO) and sympathetic nerve activity is disrupted by normal aging. We hypothesize that this relationship is not disrupted but that healthy older subjects have lower cardiac outputs and proportionally higher sympathetic activity than young subjects. Our secondary hypothesis is that women have a similar CO-MSNA relationship to men, but for any given CO, sympathetic activity is lower in women. A tertiary hypothesis is that baseline MSNA will not be related to 24 hour ambulatory blood pressure measurements. Specific Aim 2: We will test whether changes in blood volume and CO with normal aging are linked to the increase in MSNA by using volume expansion and lower body negative pressure to manipulate CO. We hypothesize that sympathetic activity will be similar at a given CO and arterial pressure in both older and younger subjects. Specific Aim 3: We will test whether a1- versus a2-adrenergic receptors are involved in the decreased vascular responsiveness seen in normotensive subjects with high MSNA. We hypothesize there will be an inverse relationship between baseline MSNA and vascular responsiveness that will be most obvious for a1-receptors in both younger and older subjects. We also propose exploratory analysis of genomic variation in a1- and a2-adrenergic receptors and related pathways from subjects with varying levels of baseline sympathetic activity. Specific Aim 4: We will test whether baroreflex control of MSNA is related to baseline MSNA and how this changes with aging. We hypothesize that subjects with high baseline MSNA will demonstrate blunted baroreflex control of MNSA. In summary, this overall approach will permit us to understand how normotensive is maintained in humans with high baseline sympathetic activity and set the stage for understanding how these mechanisms might fail in hypertension.
描述(由申请人提供):该提案探讨了年轻人和老年人交感血管收缩活性和血压调节之间的平衡。虽然基线交感神经活动(MSNA)在血压正常的年轻男性中是稳定的,但基线MSNA存在广泛的个体间差异,并且MSNA与动脉压之间没有明确的关系。此外,交感神经活动随着正常衰老而增加,但并不总是与动脉压的显著增加相关。在这种情况下,我们最近的研究表明,交感神经活动,心输出量和血管收缩反应肾上腺素能刺激之间的平衡可能解释了动脉压保持正常时,基线交感神经活动是高的。通过探索以下具体目标,我们测试了总体假设,即血压正常的年轻和老年受试者的高基线交感神经活动通过心输出量和血管肾上腺素能反应性的相互变化来平衡,这限制了交感神经兴奋的血压升高影响。具体目标1:我们将测试心输出量(CO)和交感神经活动之间的相互关系是否会被正常衰老破坏。我们假设这种关系没有被破坏,但健康的老年人有较低的心输出量和比例较高的交感神经活动比年轻的受试者。我们的次要假设是,女性与男性有类似的CO-MSNA关系,但对于任何给定的CO,女性的交感神经活动较低。第三个假设是基线MSNA与24小时动态血压测量值无关。具体目标二:我们将测试是否与正常老化的血容量和CO的变化与MSNA的增加,通过使用体积扩张和下体负压来操纵CO。我们假设,交感神经活动将是相似的,在一个给定的CO和动脉压在老年人和年轻人的主题。具体目标3:我们将测试是否a1-与a2-肾上腺素能受体参与了在高MSNA的血压正常受试者中观察到的血管反应性降低。我们假设基线MSNA和血管反应性之间存在反比关系,这在年轻和老年受试者中对α 1受体最为明显。我们还提出了探索性分析的基因组变异的α 1和α 2肾上腺素能受体和相关途径的主题与不同水平的基线交感神经活动。具体目标4:我们将测试MSNA的压力反射控制是否与基线MSNA相关,以及这种控制如何随年龄变化。我们假设基线MSNA高的受试者将表现出对MNSA的压力反射控制减弱。总之,这种整体方法将使我们能够了解如何在具有高基线交感神经活动的人类中维持正常血压,并为理解这些机制如何在高血压中失败奠定基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL J JOYNER其他文献

MICHAEL J JOYNER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL J JOYNER', 18)}}的其他基金

Variant Hemoglobin and Cardiorespiratory Regulation in Humans
人类变异血红蛋白和心肺调节
  • 批准号:
    10320441
  • 财政年份:
    2018
  • 资助金额:
    $ 37.52万
  • 项目类别:
Variant Hemoglobin and Cardiorespiratory Regulation in Humans
人类变异血红蛋白和心肺调节
  • 批准号:
    10532798
  • 财政年份:
    2018
  • 资助金额:
    $ 37.52万
  • 项目类别:
Variant Hemoglobin and Cardiorespiratory Regulation in Humans
人类变异血红蛋白和心肺调节
  • 批准号:
    10065009
  • 财政年份:
    2018
  • 资助金额:
    $ 37.52万
  • 项目类别:
Perfusion of Active Muscles: Metabolites and Nerves
活跃肌肉的灌注:代谢物和神经
  • 批准号:
    7822178
  • 财政年份:
    2009
  • 资助金额:
    $ 37.52万
  • 项目类别:
Neurovascular Control in Postural Tachycardia Syndrome (POTS)
姿势性心动过速综合征 (POTS) 的神经血管控制
  • 批准号:
    7640798
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
Neurovascular Control and Blood Pressure Regulation in Humans
人类神经血管控制和血压调节
  • 批准号:
    8710314
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:
Neurovascular Control and Blood Pressure Regulation in Humans
人类神经血管控制和血压调节
  • 批准号:
    8307651
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:
Neurovascular Control and Blood Pressure Regulation in Humans
人类神经血管控制和血压调节
  • 批准号:
    8532123
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:
Neurovascular Control and Blood Pressure Regulation in Humans
人类神经血管控制和血压调节
  • 批准号:
    8879184
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:
Neurovascular Control and Blood Pressure Regulation in Humans
人类神经血管控制和血压调节
  • 批准号:
    9086411
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:

相似海外基金

Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8358448
  • 财政年份:
    2012
  • 资助金额:
    $ 37.52万
  • 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
  • 批准号:
    8517552
  • 财政年份:
    2012
  • 资助金额:
    $ 37.52万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7952159
  • 财政年份:
    2009
  • 资助金额:
    $ 37.52万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7952152
  • 财政年份:
    2009
  • 资助金额:
    $ 37.52万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7719194
  • 财政年份:
    2008
  • 资助金额:
    $ 37.52万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7605416
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
  • 批准号:
    7605425
  • 财政年份:
    2007
  • 资助金额:
    $ 37.52万
  • 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
  • 批准号:
    7378753
  • 财政年份:
    2006
  • 资助金额:
    $ 37.52万
  • 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
  • 批准号:
    6825160
  • 财政年份:
    2004
  • 资助金额:
    $ 37.52万
  • 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
  • 批准号:
    2702283
  • 财政年份:
    1997
  • 资助金额:
    $ 37.52万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了